Arrowhead Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ARWR Nasdaq 2830 arrowheadpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arrowhead Pharmaceuticals, Inc.

ARWR: Acquires PRV for sNDA Submission for Plozasiran in sHTG - Aug 5th, 2026 7:38 am
Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... - Aug 4th, 2026 11:05 pm
Arrowhead Pharmaceuticals Q3 Earnings Call Highlights - Aug 4th, 2026 4:03 pm
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results - Aug 4th, 2026 2:01 pm
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher - Aug 4th, 2026 2:00 pm
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Aug 3rd, 2026 2:30 pm
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Dual Phase 3 RNAi Cardiometabolic Milestones - Jul 30th, 2026 3:09 am
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Jul 27th, 2026 5:30 am
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Jul 23rd, 2026 12:11 pm
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? - Jul 23rd, 2026 9:00 am
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - Jul 22nd, 2026 4:44 pm
Sector Update: Healthcare Stocks Softer Late Afternoon - Jul 22nd, 2026 1:48 pm
Arrowhead (ARWR) Soars to New High as Plozasiran Nears Expanded Commercialization - Jul 22nd, 2026 1:05 pm
Top Midday Gainers - Jul 22nd, 2026 11:41 am
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Jul 22nd, 2026 7:08 am
Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR) - Jul 22nd, 2026 6:23 am
ARWR: SHASTA-3 and SHASTA-4 Hit on All Endpoints Including 100% Reduction in Acute Pancreatitis in High-Risk Patients - Jul 22nd, 2026 6:15 am
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug - Jul 22nd, 2026 6:01 am
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia - Jul 22nd, 2026 5:30 am
Arrowhead Pharmaceuticals (ARWR) Stock Looks Fairly Priced With Strong Sales But A Demanding 398% Run - Jul 22nd, 2026 5:10 am